Five things to watch in markets in the week ahead
LONDON - Avacta Group PLC (AIM:AVCT) will present data on its first dual-payload peptide drug conjugate at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25, according to a press release issued Monday.
The presentation will showcase in vitro proof of mechanism for the company’s pre|CISION platform innovation, which enables two complementary cancer drugs to be delivered via a single molecule.
The technology is designed to allow selective and controlled release of two cancer-targeting payloads directly in the tumor through fibroblast activation protein (FAP) cleavage. FAP is expressed in more than 90% of solid tumors, according to the company.
"This new IP builds on the success of our FAP-EXd (AVA6103) program, where we invented a sustained release delivery mechanism with the platform," said Christina Coughlin, Chief Executive Officer of Avacta.
The presentation, titled "Discovery and characterization of novel pre|CISION technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage," will be delivered by Francis Wilson during Poster Session C.
Drug combinations are commonly used in cancer therapy to improve outcomes and address resistance. Avacta states this approach extends their technology to potentially treat highly-resistant cancers by targeting key resistance mechanisms.
Previously, the company’s development efforts focused on optimizing the delivery of single payloads to the tumor microenvironment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.